244 related articles for article (PubMed ID: 25204805)
1. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
[TBL] [Abstract][Full Text] [Related]
2. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
3. Use of statins and the risk of death in patients with prostate cancer.
Yu O; Eberg M; Benayoun S; Aprikian A; Batist G; Suissa S; Azoulay L
J Clin Oncol; 2014 Jan; 32(1):5-11. PubMed ID: 24190110
[TBL] [Abstract][Full Text] [Related]
4. The use of metformin in patients with prostate cancer and the risk of death.
Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):2111-8. PubMed ID: 25017246
[TBL] [Abstract][Full Text] [Related]
5. The use of aspirin and the risk of mortality in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
J Urol; 2015 Apr; 193(4):1220-5. PubMed ID: 25463991
[TBL] [Abstract][Full Text] [Related]
6. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
[TBL] [Abstract][Full Text] [Related]
8. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
[TBL] [Abstract][Full Text] [Related]
9. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes and the risk of mortality among patients with prostate cancer.
Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
Cancer Causes Control; 2014 Mar; 25(3):329-38. PubMed ID: 24384808
[TBL] [Abstract][Full Text] [Related]
11. A cohort study of digoxin exposure and mortality in men with prostate cancer.
Flahavan EM; Sharp L; Bennett K; Barron TI
BJU Int; 2014 Feb; 113(2):236-45. PubMed ID: 23937513
[TBL] [Abstract][Full Text] [Related]
12. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
13. Physical activity and survival among men diagnosed with prostate cancer.
Bonn SE; Sjölander A; Lagerros YT; Wiklund F; Stattin P; Holmberg E; Grönberg H; Bälter K
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):57-64. PubMed ID: 25527697
[TBL] [Abstract][Full Text] [Related]
14. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Margel D; Urbach DR; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
J Clin Oncol; 2013 Sep; 31(25):3069-75. PubMed ID: 23918942
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and mortality in men with prostate cancer.
Cantarutti A; Bonn SE; Adami HO; Grönberg H; Bellocco R; Bälter K
Prostate; 2015 Aug; 75(11):1129-36. PubMed ID: 25929695
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and weight change in men with prostate cancer: progression and mortality.
Bonn SE; Wiklund F; Sjölander A; Szulkin R; Stattin P; Holmberg E; Grönberg H; Bälter K
Cancer Causes Control; 2014 Aug; 25(8):933-43. PubMed ID: 24810654
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
Holmes S; Griffith EJ; Musto G; Minuk GY
Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
[TBL] [Abstract][Full Text] [Related]
18. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients.
Hicks BM; Murray LJ; Hughes C; Cardwell CR
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):830-40. PubMed ID: 26017274
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
Botteri E; Munzone E; Rotmensz N; Cipolla C; De Giorgi V; Santillo B; Zanelotti A; Adamoli L; Colleoni M; Viale G; Goldhirsch A; Gandini S
Breast Cancer Res Treat; 2013 Aug; 140(3):567-75. PubMed ID: 23912960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
